Dendrogenix doses first patient in Phase IIa with DX243 for age-related hearing loss

119
Posted on : 03-06-2026 | News Dendrogenix today announced that the first patient has been dosed in the Phase IIa clinical trial evaluating DX243 in patients with age-related hearing loss, also known as presbycusis. This milestone represents a major step forward in the development of DX243, a potentially first-in-class pharmacological…

Gramitherm now has a new Facebook page!

261
30 October 2025. We are growing and we have a new Facebook page!   We are delighted to invite you to discover Gramitherm’s new official Facebook page! Follow us to stay informed about: – Our latest product innovations – Our sustainable projects and achievements – Our advice and news on…

Institute of Pathology and Genetics – IPG: Advanced expertise for innovative diagnostics and treatments

© IPG
1K

The Institut de Pathologie et de Génétique is a non-profit association founded in Charleroi, Belgium in 1958. It has 350 highly specialized and dedicated staff. Each year it carries out more than 450,000 analyses. The IPG’s activity is based on 3 essential pillars: anatomic pathology, the molecular biology laboratory and the human genetics centre, one of 8 such centres in Belgium. A far-reaching expertise & thrilling outlook! 🧬